Study to be conducted by PharmaLegacy, a leading Contract Research Organization The scientific rationale for evaluating ...

The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's developments will crystallize.

The free-for-all-era of weight-loss copycats is ending, but will likely morph into something else.

As President Trump hails pricing agreements with the pharmaceutical industry, some biotech companies are worried they have been left out in the cold.

And there's more than one way to monetize this technology.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 / New to The Street, the nationally syndicated, long-form ...

Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. | Eli Lilly and Innovent Biologics have ...

Sanofi has replaced its CEO Paul Hudson after a series of R&D setbacks at the French pharma, handing the reins to Merck KGaA leader Belén Garijo.

Ascendis Pharma A/S reports €684 million revenue and positive 4Q profit; Yorvipath and TransCon CNP drive growth. See why ASND stock is a buy.

Prices for GLP-1s are falling fast, forcing companies to adapt.

Novartis CEO Vas Narasimhan received $32.4 million in total realized compensation in 2025, a marked increase compared to his take home pay in 2024. Narasimhan received 24.9 million Swiss Francs last ...

As the pharma patent cliff approaches, delve into which important drug are about to lose exclusivity and how the industry is reacting.